PSTX - Poseida Therapeutics EPS beats by $0.07 November, 09 2021 04:58 PM Poseida Therapeutics Inc. Poseida Therapeutics (NASDAQ:PSTX): Q3 GAAP EPS of -$0.68 beats by $0.07. Cash, cash equivalents and short-term investments of $197.81M. Press Release For further details see: Poseida Therapeutics EPS beats by $0.07